Kentucky 2025 Regular Session

Kentucky House Bill HB174

Introduced
1/9/25  
Refer
1/9/25  

Caption

AN ACT relating to undesignated glucagon.

Impact

The bill's enactment is expected to positively impact state laws regarding emergency medical care in educational settings. It facilitates a process for schools to stock glucagon without requiring each student to have a prescription, making it more accessible during emergencies. This legislation will likely lead to a more standardized response protocol for handling severe diabetic incidents in schools, which could improve student safety and health outcomes.

Summary

House Bill 174 seeks to establish a framework around the administration of undesignated glucagon in schools. The bill allows authorized entities, such as public, private, or parochial schools, to acquire and stock glucagon for use in emergencies, particularly for students experiencing severe hypoglycemia. A key feature of the bill is the requirement for trained individuals to be present at these schools, who can administer glucagon in emergencies when a school nurse or practitioner is not available. This provision aims to enhance the safety and response measures for students suffering from diabetes-related health issues.

Sentiment

General sentiment around HB174 appears to be supportive, especially among healthcare professionals and educators who recognize the necessity of having life-saving medications readily available in schools. However, some concerns persist regarding the training adequacy for individuals appointed to administer glucagon and the overarching implications of such responsibilities placed on school staff. The bill's primary focus on emergency readiness resonates well with advocates for children's health and safety.

Contention

A notable point of contention surrounding the bill involves the potential liability implications for trained individuals and authorized entities when administering glucagon. While the bill includes provisions for civil immunity, concerns remain about the training individuals receive and the risk of adverse events occurring during emergency situations. Additionally, the requirement for schools to report the existence and location of glucagon stocks to local emergency services may raise logistical challenges, which could result in administrative burdens for school staff.

Companion Bills

No companion bills found.

Similar Bills

KY HB75

AN ACT relating to undesignated glucagon.

NJ A1882

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

NJ A5066

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

KY HB438

AN ACT relating to undesignated glucagon.

DC B25-0226

Access to Emergency Albuterol and Glucagon Amendment Act of 2023 (now known as "Access to Emergency Medications Amendment Act of 2023")

WI AB450

Ready-to-use glucagon rescue therapies in schools.

WI SB447

Ready-to-use glucagon rescue therapies in schools.

WV SB92

Glucagon for Schools Act